Compare YSG & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSG | CMPX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.0M | 752.4M |
| IPO Year | 2020 | N/A |
| Metric | YSG | CMPX |
|---|---|---|
| Price | $4.37 | $5.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.44 |
| AVG Volume (30 Days) | 336.9K | ★ 1.9M |
| Earning Date | 11-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $571,300,568.00 | N/A |
| Revenue This Year | $28.96 | N/A |
| Revenue Next Year | $16.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.59 | N/A |
| 52 Week Low | $3.01 | $1.33 |
| 52 Week High | $11.57 | $5.86 |
| Indicator | YSG | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 52.34 |
| Support Level | $3.30 | $5.09 |
| Resistance Level | $5.73 | $5.44 |
| Average True Range (ATR) | 0.42 | 0.34 |
| MACD | -0.12 | -0.07 |
| Stochastic Oscillator | 33.91 | 31.42 |
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.